Esperion Therapeutics Cash Flow - Quarterly (NASDAQ:ESPR)

Add to My Stocks
$36.13 $0.92 (2.48%) ESPR stock closing price Apr 26, 2017 (Closing)

The Esperion Therapeutics cash flow statement is one of the important reports considered by investors doing a fundamental analysis of the company. In simple terms, the cash flow statement measures the cash that has come into the company, and the cash that has gone out during a given period, while the other statements, the income statement and balance sheet, give details about Esperion Therapeutics profits and Esperion Therapeutics debt. Items like capital purchases, bank loan payments etc. which have a direct impact on the cash position of a company come out through the statemement of cash flows and help an investor who undertakes the Esperion Therapeutics stock analysis. Esperion Therapeutics generated $-47.73M cash from operating activities in 2016-Q4. Esperion Therapeutics had an outflow of $16.32M from operating activities, $0.41M spend due to financing activities, and $7.75M gain due to investing activities for 2016-Q4. View details of Esperion Therapeutics cash flows for latest & last 40 quarters.

show more
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec. 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3
Esperion Therapeutics Net Income Cash Flow
Depreciation Depletion Amortization Cash-Flow1.31M0.99M0.64M0.33M0.94M0.61M0.32M0.1M0.39M0.28M
Net Increase (Decrease) in Assets Liabilities9.98M1.23M2.18M-0.1M-2.08M-1.99M0.69M0.02M0.25M0.16M
Cash From (used in) Discontinued Operations----------
Other Adjustments Net15.95M12.38M8.67M4.55M12.77M8.33M4.97M2.07M3.71M2.65M
Esperion Therapeutics Net Cash from (used by) Operating Activities
Increase (Decrease) in Prop Plant And Equipment-0.09M-0.01M-0.01M--0.3M-0.08M-0.01M-0.01M-0.86M-0.84M
Acquisition Disposition of Subsidiaires----------
Increase (Decrease) in Investments10.21M2.37M-10.69M-29.96M-159.76M-165.32M-128.13M-57.54M-35.73M3.12M
Other Cash Inflow (Outflow) from Investment Activities----------
Esperion Therapeutics Net Cash from (used by) Invesment Activities
Issuance (Purchase) of Equity Shares0.04M0.04M0.03M0.02M191.16M191.15M190.78M190.41M92.28M0.38M
Issuance (Repayment) of Debt Securities-1.6M-1.19M-0.78M-0.39M-0.63M-0.25M--4.83M4.83M
Increase (Decrease) in Bank & Other Borrowings----------
Payment of Dividends & Other Cash Distributions----------
Other Cash from (used by) Financing Activities----------
Esperion Therapeutics Net Cash from (used by) Financing Activities
Effect of Exchange Rate Changes on Cash----------
Esperion Therapeutics Net Change in Cash & Cash Equivalents
Cash & Equivalents at Beginning of Year77.33M85.03M56.53M6.51M1.57M3.41M----
Cash & Equivalents at Year End38.16M47.14M48.76M37.2M77.33M80.82M129.78M208.64M85.03M40.23M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters
Get Cash flow for another ticker

Esperion Therapeutics stock comparison chart provides an easy way to compare the stock price with peers along with details of Esperion Therapeutics stock price history.
The statement of cash flows can be categorized into three main sections:
  • Net Change in Cash and Cash Equivalents: Esperion Therapeutics cash reduced QoQ to $-74.97M, meaning the company is unable to meet its expenditure and grow cash which will also eventually reflect in the Esperion Therapeutics stock price movement.
  • Cash Flow from operating activities: Esperion Therapeutics reported a negative operating cash flow of $-47.73M for 2016-Q4 and has seen a decrease from the previous quarter. Operating cash flow or working capital comes from main business activities. Investors look for positive cash flow from recurring operating activities.
  • Cash Flow from investment activities: Esperion Therapeutics generated $7.75M cash due to investment activities. It includes the use of cash outside of normal day to day activities like buying fixed assets, plant and machinery etc.
  • Cash flow from financing activities shows the flow of cash between Esperion Therapeutics and its owners and creditors and was $-1.55M for 2016-Q4. Financing activities allow a company to raise capital, and repay bondholders.